BATTELLE SIGNS RESEARCH AGREEMENT WITH EIFFEL TECHNOLOGIES.

Battelle Pulmonary Therapeutics Inc. (BPT), Columbus, has signed a research collaboration agreement with Eiffel Research & Development Pty Ltd (ERD), a subsidiary of Melbourne, Australia-based Eiffel Technologies Limited. Under the terms of the agreement, ERD will use its Super Critical Fluid (SCF) technology to produce and supply sub-micron size drug particles of a protein for testing in BPT's proprietary electrohydrodynamic (EHD) or Mystic(TM) pulmonary delivery device.

"We believe the combination of the SCF technology and our Mystic delivery system will enhance the performance and bioavailability of BPT's proprietary drugs and those we have in development with our pharmaceutical partners," said Donna Palmer, vice president, pharmaceutical research and development for BPT. "Nanoparticle technology allows us to continue to leverage Mystic's ability to control and deliver fine aerosol droplets and maintain a consistent and high drug load."

EHD is BPT's proprietary approach to aerosolizing liquids for pulmonary delivery of drugs. The Mystic device delivers particles directly to the lungs with better than 90 percent efficiency, and without the need for liquid propellants or other pressurized systems. The device comes in small, convenient sizes and can be adapted to deliver a wide range of medications. EHD inhalers provide efficient, accurate, and reproducible dosing and have optimal ergonomics.

About BPT

Battelle Pulmonary Therapeutics Inc. is a specialty pharmaceutical company leveraging science and engineering for more effective medicines. Using its proprietary Mystic(TM) technology, the company develops its own products in cancer and asthma and has development agreements with leading pharmaceutical companies for asthma, COPD, respiratory infections and systemic diseases. BPT is a pre-public subsidiary of Battelle Memorial Institute, the world's largest research and consulting organization.

For more information, visit http://www.bpt-inc.com.